Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The BRAIN (Bolstering Research And Innovation Now) Act directs federal actions to advance brain tumor research, improve patient access to clinical trials, and strengthen survivorship care. Key provisions create a public registry for NIH-funded brain tumor biospecimens, authorize new NIH programs and funding for glioblastoma and cellular immunotherapy research, establish a national awareness campaign and demonstration grants for clinical trial and biomarker testing outreach, fund pilot survivorship programs, and require FDA guidance to reduce exclusion of brain tumor patients from trials.
Adequacy of authorized funding versus disease burden and need.
Relative to its intended legislative type, this bill is a substantive package that establishes new statutory authorities, reporting obligations, and authorized funding streams to bolster brain tumor research, awareness, and survivorship care.
The BRAIN (Bolstering Research And Innovation Now) Act directs federal actions to advance brain tumor research, improve patient access to clinical trials, and strengthen survivorship care.
Key provisions create a public registry for NIH-funded brain tumor biospecimens, authorize new NIH programs and funding for glioblastoma and cellular immunotherapy research, establish a national awareness campaign and demonstration grants for clinical trial and biomarker testing outreach, fund pilot survivorship programs, and require FDA guidance to reduce exclusion of brain tumor patients from trials.
Technocratic, bipartisan-appealing package with modest, targeted authorizations; passage depends largely on appropriations and committee prioritization.
Relative to its intended legislative type, this bill is a substantive package that establishes new statutory authorities, reporting obligations, and authorized funding streams to bolster brain tumor research, awareness, and survivorship care. It is generally well-structured in its amendments to the Public Health Service Act and in assigning responsibilities to specific agencies and officials.
Adequacy of authorized funding versus disease burden and need.
These are examples from the analysis, not a ranked list of the most-affected groups.
Adequacy of authorized funding versus disease burden and need.
Likely broadly supportive: the bill funds targeted research, increases transparency of biospecimens, promotes access to trials, and directs attention to survivorship and equity-focused outreach.
Supporters would press for larger funding, strong patient protections, and explicit equity measures.
Generally supportive in principle: the bill is targeted, bipartisan, and focused on research and patient outreach.
Centrists will seek clear cost estimates, measurable outcomes, and efficient implementation to avoid redundancy and waste.
Cautious support for the goal of improving treatments, but concerns about new federal mandates, administrative burdens, and unoffset authorized spending.
Conservatives will emphasize limiting regulatory overreach and protecting privacy and proprietary interests.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technocratic, bipartisan-appealing package with modest, targeted authorizations; passage depends largely on appropriations and committee prioritization.
The bill has not accumulated any surfaced votes yet.
Adequacy of authorized funding versus disease burden and need.
Technocratic, bipartisan-appealing package with modest, targeted authorizations; passage depends largely on appropriations and committee pr…
Relative to its intended legislative type, this bill is a substantive package that establishes new statutory authorities, reporting obligations, and authorized funding streams to bolster brain tumor research, awareness,…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.